Mast Group Enters into Multi-Country Distribution Agreement for Nanomix's eLab System
|
By LabMedica International staff writers Posted on 07 Nov 2022 |
|
Mast Group Limited (Liverpool, UK) and Nanomix (Emeryville, CA, USA) have entered into a multi-region distribution agreement wherein Mast will market and distribute the Nanōmix eLab system in the UK, Germany, France, Ireland and South Africa.
The Nanōmix eLab system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type. The assay runs on the eLab Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration.
“This new agreement with Mast Group becomes our largest expansion to date within Europe for the Nanomix eLab system,” said Thomas Schlumpberger, Chief Executive Officer of Nanomix. “The Nanomix solution is a unique, breakthrough technology that offers mobile, timely diagnostic capability from a whole blood sample. The eLab system will help expedite sepsis and pneumonia diagnosis leading to more informed treatment decisions, thus improving patient outcomes and hospital clinical collaboration.”
“It has been a pleasure working with The Mast Group to bring this agreement to fruition. Mast has significant experience and presence in this increasingly complex and important area of critical infections, sepsis, and antibiotic stewardship,” said John Hardesky, Chief Commercial Officer of Nanomix. “Their team is experienced and is actively participating in clinical conversations and solutions to improve patient outcomes and impact hospital performance. We are excited to actively align with Mast on an aggressive execution plan to bring our technology to multiple markets throughout Europe.”
“The Mast Group has always been proud of its commitment and ability to offer innovative diagnostic products that help our customers,” added Sandy Daun, Sales and Marketing Director of Mast Group. “We are pleased to begin this long-term, strategic relationship with Nanomix which reinforces that commitment. The platform technology provides the right foundation for assay expansions which will complement the growth areas important to Mast and our customers.”
Related Links:
Mast Group Limited
Nanomix
Latest Industry News
- Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
- Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
- New Collaboration to Advance Microbial Identification for Infectious Disease Diagnostics
- Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
- Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration
- Philips and Ibex Expand Partnership to Enhance AI-Enabled Pathology Workflows
- Grifols and Inpeco Partner to Deliver Transfusion Medicine ‘Lab of The Future’
- Research Collaboration to Advance AI-Enhanced, Real-Time Optical Imaging in Lung Cancer Biopsy
- CACLP 2025 Unites Global Innovators in IVD Industry
- Bio-Rad to Acquire Digital PCR Developer Stilla Technologies
- ABL Signs Know-How License and Transfer Agreement for Siemens’ Fast Track Diagnostics PCR Portfolio
- Becton Dickinson to Spin Out Biosciences and Diagnostic Solutions Business
- New Partnership Revolutionizes Analyses of Biological Samples
- Medlab Middle East Looks to The Future of Laboratories
- Medix Biochemica Acquires German Immunoassay Solutions Developer Candor Bioscience
- bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more
Molecular Diagnostics
view channel
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
